New concerns about old drugs: Valvular heart disease on ergot derivative dopamine agonists as an exemplary situation of pharmacovigilance

Editorial

Olivier Rascol et al. Mov Disord. 2004 Jun.

. 2004 Jun;19(6):611-3.

doi: 10.1002/mds.20202.

No abstract available

Comment in

Fibrotic valvular heart disease is not related to chemical class but to biological function: 5-HT2B receptor activation plays crucial role.
Horowski R, Jähnichen S, Pertz HH. Horowski R, et al. Mov Disord. 2004 Dec;19(12):1523-4. doi: 10.1002/mds.20329. Mov Disord. 2004. PMID: 15515006 No abstract available.
Valvular heart disease and fibrotic reactions may be related to ergot dopamine agonists, but non-ergot agonists may also not be spared.
Chaudhuri KR, Dhawan V, Basu S, Jackson G, Odin P. Chaudhuri KR, et al. Mov Disord. 2004 Dec;19(12):1522-3. doi: 10.1002/mds.20330. Mov Disord. 2004. PMID: 15515009 No abstract available.

Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists.
Horvath J, Fross RD, Kleiner-Fisman G, Lerch R, Stalder H, Liaudat S, Raskoff WJ, Flachsbart KD, Rakowski H, Pache JC, Burkhard PR, Lang AE. Horvath J, et al. Mov Disord. 2004 Jun;19(6):656-62. doi: 10.1002/mds.20201. Mov Disord. 2004. PMID: 15197703
Diagnosis and management of pergolide-induced fibrosis.
Agarwal P, Fahn S, Frucht SJ. Agarwal P, et al. Mov Disord. 2004 Jun;19(6):699-704. doi: 10.1002/mds.20200. Mov Disord. 2004. PMID: 15197712